Sandhoff disease study shows proof of principle for gene therapy

February 22, 2018, American Society for Biochemistry and Molecular Biology
Researchers at NIH compared cerebral organoids grown from a Sandhoff disease patient's induced pluripotent stem cells to organoids from cells corrected with CRISPR/Cas9 technology and found a surprising overgrowth phenotype early in development. Treatment with a gene therapy vector in early clinical studies for related diseases restored Sandhoff organoids to a normal phenotype. Credit: Richard Proia, NIDDK

Babies with the rare, deadly genetic disorder Sandhoff disease begin to miss developmental milestones just months after birth. Lacking muscle tone, they never learn to sit up, develop heads too large to lift and eventually suffer uncontrollable seizures. There is no cure.

"With excellent supportive care, children can survive until age 5 or so," said Dr. Cynthia Tifft of the National Human Genome Research Institute, part of the National Institutes of Health.

A paper appearing in the March 1 issue of the Journal of Lipid Research by senior investigators Tifft and Richard Proia and lead author Laura Allende of NIH's National Institute of Diabetes and Digestive and Kidney Diseases, and their colleagues, describes an important step toward gene therapy for patients with Sandhoff .

The disease is a lysosomal storage disorder. Enzymes in the lysosome normally break down unneeded molecules. When one doesn't work, the molecule it should degrade begins to accumulate.

Sandhoff disease affects an enzyme that breaks down complex lipids called gangliosides. Ganglioside accumulation eventually causes cell death in the brain and spinal cord.

The first human model for Sandhoff disease

The researchers wanted to know whether the problems that appear very soon after birth in Sandhoff patients actually develop during pregnancy. The disease is ultra-rare; Tifft estimates five children are born with it in the U.S. each year. Therefore, most of what is known about the disease comes from studying genetically engineered mice, which are not a perfect comparison.

This study began when a baby with Sandhoff disease came to Tifft's clinic, where the medical geneticist treats patients with infantile and milder adult-onset forms of the disease. Researchers took from the baby and reprogrammed them into induced pluripotent . Those cells, like the ones in an embryo, can mature into any cell type in the body.

The team created healthy control cells by using CRISPR/Cas9 genome editing to correct one copy of the affected gene in the patient's stem cells. The researchers then induced the two sets of stem cells to grow into simple groups of brain cells called organoids, about the size of the eraser on a pencil. The researchers compared the healthy and Sandhoff-affected organoids to find out how the disturbed enzyme might affect early development.

Unexpected problems with development

As expected, researchers saw accumulation of ganglioside molecules in the Sandhoff organoids. The healthy organoids did not show this accumulation, confirming that the genetic intervention had worked. But the researchers also found something surprising.

"The major feature of this disease, in humans and in mouse models, is the neurodegeneration," Proia explained. But instead of cell death in the Sandhoff disease organoids, the researchers saw cell overgrowth. Although there was no difference between the stem cells, the Sandhoff organoids were much larger than the healthy ones, mimicking the large brains of patients.

The profile of expressed in the healthy organoids looks a lot like the first trimester of pregnancy. However, the researchers found that the organoids with Sandhoff disease had changes in genes that govern cell maturation. Instead of settling into a role as differentiated adult cells, the Sandhoff cells just kept growing. It remains to be determined how the disrupted ganglioside enzyme leads to changes in gene expression.

"Most of us have been thinking of lysosomal storage diseases as if everything is just fine until these molecules begin to build up," said Ron Schnaar, a professor at Johns Hopkins University who researches gangliosides in the brain and was not involved in this study. "But there has always been a bubbling issue of whether the molecules themselves have an effect, other than building up to tremendous amounts."

Schnaar said this paper is the first to address that question, showing that disruption of gangliosides does affect brain development in humans.

A path toward Sandhoff disease gene therapy

CRISPR, the researchers' original approach to correct the gene, is still far from the clinic. Therefore, the researchers also tested a more practical gene-therapy approach, which had already been successful in animal models of Sandhoff disease.

They used a virus to introduce the gene to Sandhoff organoids that were 4 weeks old. About two weeks after receiving the gene therapy, the organoids that had been treated were closer in size to the healthy organoids and no longer had large clumps of the ganglioside.

"That's the first proof of principle in a human model system that gene therapy may actually be beneficial for these kids," said Tifft. The viral gene-therapy approach is in clinical studies for other lysosomal storage disorders, and the first FDA-approved for any genetic disorder uses a similar virus.

Unfortunately, the patient whose skin were used for this study died at age 4. While it comes too late for her, the research strikes a hopeful note for future generations of children with Sandhoff disease.

Explore further: Promising therapy for fatal genetic diseases in children nears human trials

More information: Maria L. Allende et al, Cerebral organoids derived from Sandhoff disease induced pluripotent stem cells exhibit impaired neurodifferentiation, Journal of Lipid Research (2018). DOI: 10.1194/jlr.M081323

Related Stories

Promising therapy for fatal genetic diseases in children nears human trials

July 18, 2017
Researchers at University of Massachusetts Medical School and Auburn University College of Veterinary Medicine are nearing human clinical trials on a genetic therapy for two rare neurological diseases that are fatal to children.

Promising results with new gene therapy approach for treating inherited neurodegenerative diseases

July 28, 2016
A new gene therapy approach designed to replace the enzyme that is deficient in patients with the inherited neurodegenerative disorders Tay-Sachs and Sandhoff diseases successfully delivered the therapeutic gene to the brains ...

Mini brains may wrinkle and fold just like ours

December 18, 2017
Flat brains growing on microscope slides may have revealed a new wrinkle in the story of how the brain folds.

Modular approach found to improve consistency of organoids

August 15, 2017
(Medical Xpress)—A team of researchers from the U.S. and Australia working at the Yale Stem Cell Center report that they have met with some success in improving the usefulness of organoids. In their paper published in the ...

Patient-derived organoids may help personalize the treatment of gastrointestinal cancers

January 17, 2018
A new BJS (British Journal of Surgery) review highlights the potential of 3D organoid models derived from patient cells to help personalize therapy for individuals with gastrointestinal cancers.

Recommended for you

Exercise-induced hormone irisin triggers bone remodeling in mice

December 13, 2018
Exercise has been touted to build bone mass, but exactly how it actually accomplishes this is a matter of debate. Now, researchers show that an exercise-induced hormone activates cells that are critical for bone remodeling ...

Law professor suggests a way to validate and integrate deep learning medical systems

December 13, 2018
University of Michigan professor W. Nicholson Price, who also has affiliations with Harvard Law School and the University of Copenhagen Faculty of Law, suggests in a Focus piece published in Science Translational Medicine, ...

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Pain: Perception and motor impulses arise in brain independently of one another

December 13, 2018
Pain is a negative sensation that we want to get rid of as soon as possible. In order to protect our bodies, we react by withdrawing the hand from heat, for example. This action is usually understood as the consequence of ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Researchers give new insight to muscular dystrophy patients

December 13, 2018
New research by University of Minnesota scientists has revealed the three-dimensional structure of the DUX4 protein, which is responsible for the disease, facioscapulohumeral muscular dystrophy (FSHD). Unlike the majority ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.